Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.

Molecular oncology - 1 Oct 2022

Zhang Lanxin, Sun Siwen, Zhao Xiaotian, Liu Jingwen, Xu Yang, Xu Lingzhi, Song Chen, Li Na, Yu Jing, Zhao Shanshan, Yu Peiyao, Fang Fengqi, Xie Jiping, Ji Xuening, Yu Ruoying, Ou Qiuxiang, Zhao Zuowei, Li Man

Abstract excerpt

Approximately 30% of breast cancer (BC) patients suffer from disease relapse after definitive treatment. Monitoring BC at baseline and disease progression using comprehensive genomic profiling would facilitate the prediction of prognosis. We retrospectively studied 101 BC patients ultimately experiencing relapse and/or metastases. The baseline and circulating tumor DNA-monitoring cohorts included patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Circulating Tumor DNA

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35971249
DOI: 10.1002/1878-0261.13297
PMCID: PMC9580879

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.PMID 35971249Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.Semantic proximity Read ↗

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.Semantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapySemantic proximity Read ↗

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysisSemantic proximity Read ↗

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapySemantic proximity Read ↗

Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer.Semantic proximity Read ↗

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.